CYTOKINETICS INC (CYTK)
Health Care · Biotechnology · NASDAQ
A clinical-stage biopharmaceutical firm pioneering muscle-directed therapies for cardiovascular and neuromuscular diseases.
What CYTOKINETICS INC does
Cytokinetics is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of muscle activators and inhibitors for the treatment of severe cardiovascular and neuromuscular diseases. Its primary product pipeline includes clinical-stage therapies for conditions such as hypertrophic cardiomyopathy (HCM) and heart failure. The company collaborates with global partners for the development and commercialization of its therapeutics in international markets.
Themes: cardiovascular disease, hypertrophic cardiomyopathy (HCM), heart failure, muscle-directed therapeutics, drug development
Fundamentals
- Price$76.84 as of 2026-08-21 close
- Market cap$10.7B as of 2026-08-21
- 1-year return+101.9% 2025-08-21 close $38.05 → 2026-08-21 close $76.84
- P/En/a negative earnings
- Net margin-1321.1% as of 2026-08-24
- ROE-131.2% as of 2026-08-24
- Debt / equity6.01 as of 2026-08-24
- Revenue growth (YoY)-21.1% as of 2026-08-24
- Revenue CAGR (3y)-2.4% SEC XBRL
- Beta0.36 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How CYTK compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
CYTK is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no valuation data.
Short-term score
55.0 #480 of 1,704 scored · #92 of 240 in Health Care
Catalysts 77th: open-market insider buys in 90 days 47, analysts have raised their average price target by 1.0% since the prior reading; volume and participation 66th: it gapped 4.1% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; weakest is setup 43rd: no fresh 20-day breakout up or down.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How CYTOKINETICS INC looks technically
CYTOKINETICS INC (CYTK) is trading 11.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 227 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 10, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It made a new 20-day low about 7 trading days ago.
Trend
8
| Distance from the 200-day | it is trading 11.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +11.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $79.51 | $79.51 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $69.10 | $69.10 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 72.12. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 227 trading days ago — a "golden cross", a bullish long-term signal | 227 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 10, below the 25 that marks a real trend) | 10.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30) | 46.9 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($72.12 to $81.77) — its "stochastic" reading is 49 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 48.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $88.31 | $88.31 |
|---|---|---|
| From the 52-week high | it is 13.0% below its 52-week high (its highest price of the past year) | -13.0% |
| Above the 52-week low | it is 118.2% above its 52-week low (its lowest price of the past year) | +118.2% |
| Below the 52-week high | it is 13.0% below its highest point of the past year | 13.0% |
| Since a 20-day breakout | it made a new 20-day low about 7 trading days ago | 7 sessions |
| Since a 55-day breakout | it made a new 55-day high about 39 trading days ago | 39 sessions |
| All-time high | its highest closing price on record is $110.25 (set on 2024-01-08) | $110.25 |
| Given back of the 52-week move | over the past year its closes ranged ($35.33 to $87.26), and it has given back roughly a quarter of its rise from last year’s low — 20% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $53.51 to $55.17. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 20.1% |
| From the all-time high | it is 30.3% below its all-time high | -30.3% |
| Nearest price level | it is trading 2.4% below a resistance level at $78.69 — a price it turned at twice since 2026-05-20, most recently on 2026-07-17. Since 2024-08-21 it has 17 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.4% |
| All-time low | its lowest closing price on record is $3.05 (set on 2014-10-13) | $3.05 |
| Above the all-time low | it is 2419.3% above its all-time low | +2,419% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 86% of it) | 14th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.56 between its high and its low — about 3.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.56 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $73.44 and $81.45 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $73.44 – $77.45 – $81.45 |
| Typical daily range (% of price) | its price moves about 3.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.3% |
| Stretch from the 200-day average | it is trading 3.0 daily ranges above its 200-day average price (11.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.88× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.0% since the prior reading | +1.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.2% |
|---|---|---|
| Open gap | it gapped 4.1% above the previous close 46 sessions ago and has not traded back through the level it left behind at 70.15 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +4.1% |
| Gap filled | a 2.6% gap down opened on 2026-07-23 has been "filled" 21 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 21 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -1.16% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 7.6 percentage points (the stock lost 5.3% while the market gained 2.3%) | -7.6% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 4.7 percentage points (the stock lost 1.6% while the market gained 3.1%) | -4.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 2.0 percentage points (the stock gained 13.1% while the market gained 11.1%) | +2.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 81.5 percentage points (the stock gained 101.9% while the market gained 20.5%) | +81.5% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 9.6% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 8% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $71.44 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +7.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is roughly break-even. That average is $76.76 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +0.1% |
Price levels it has turned at before
CYTK last closed at $76.84 on 2026-08-21. Since 2024-08-21 it has turned at 17 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $78.69 | Resistance | 2.4% above the last close | turned there twice · 2026-05-20 to 2026-07-17 |
| $72.56 | Support | 5.6% below the last close | turned there twice · 2026-05-19 to 2026-08-14 |
| $70.69 | Support | 8.0% below the last close | turned there twice · 2025-12-22 to 2026-02-24 |
| $69.02 | Support | 10.2% below the last close | turned there twice · 2025-11-28 to 2026-04-02 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $72.12.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · Trading inside the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 20 analysts
- Mean price target$109.90 range $85.00 – $146.00; median $107.50
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for CYTK
- Consensus EPS estimate-$1.44 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on clinical trial success for product candidates, which are inherently uncertain and capital-intensive.","Significant history of operating losses and dependence on financing, including royalty-based transactions and convertible debt, to fund operations.","Potential for regulatory delays or denials by the FDA, EMA, or other health authorities."]
What changed in the latest 10-Q
AI-assisted comparison of CYTK's 10-Q filed 2026-05-05 against the prior one filed 2025-11-05.
Management's Discussion & Analysis (MD&A)
- Added:
- In newer filing (2026-05-05): MYQORZO FDA approval in December 2025 and availability for prescription on or around January 27, 2026
- In newer filing (2026-05-05): European Commission approval of MYQORZO in February 2026
- In newer filing (2026-05-05): China National Medical Products Administration approval of MYQORZO in December 2025
- In newer filing (2026-05-05): MYQORZO REMS program description
- In newer filing (2026-05-05): New section 'Cytokinetics' Marketed Product: MYQORZO®' with detailed product description
- In newer filing (2026-05-05): Forward-looking statements identify specific indicators including terms 'forecast,' 'predict,' 'project,' 'seek' and reference to 'Private Securities Litigation Reform Act of 1995' safe harbor provisions
- Removed:
- In older filing (2025-11-05): Description of company as 'late-stage biopharmaceutical company'
- In older filing (2025-11-05): Reference to 'first-in-class muscle activators and next-in-class muscle inhibitors'
- In older filing (2025-11-05): Reference to 'healthspan' (spelled as one word)
- In older filing (2025-11-05): Paragraph stating 'Our research continues to drive innovation and leadership in muscle biology. All of our drug candidates have arisen from our cytoskeletal research activities.'
- In older filing (2025-11-05): Section titled 'Research and Development Programs' with subsections on 'Specialty Cardiology Programs' and detailed discussion of cardiac muscle contractility programs and HCM disease description
- In older filing (2025-11-05): Section titled 'Aficamten' (product section)
- Reworded:
- Newer filing changes 'health span' to 'health span' (consistent spelling) in the Overview section
- Newer filing removes 'first-in-class' and 'next-in-class' descriptors, referring instead to 'novel muscle activators and muscle inhibitors'
- Newer filing changes 'late-stage biopharmaceutical company' to 'biopharmaceutical company'
- Newer filing restructures Overview to emphasize MYQORZO as 'first commercial product' rather than pipeline focus
- Newer filing changes forward-looking statement language from 'We intend that such statements be protected by the safe harbor created thereby' to 'We have made these statements in reliance on the safe harbor provisions'
- Newer filing expands forward-looking statement indicators list with additional terms compared to older filing
- Newer filing changes 'year over year' to 'year-over-year' (hyphenation)
- Newer filing removes reference to HCM as 'one of the leading causes of sudden cardiac death' and removes subset discussion of progressive disease leading to dilated cardiomyopathy
- Notes:
- The newer filing text appears truncated at the end ('sudden car'), limiting full comparison of HCM disease description section
- The older filing text also appears truncated at 'Aficamten' section start, limiting full product comparison
- Structural reorganization makes direct line-by-line comparison challenging; changes reflect shifts in document organization and emphasis rather than only content modifications
Risk Factors
- Added:
- Added glossary term 'AMBER-HFpEF' with revised capitalization of 'Our' to 'Our' (filed 2026-05-05)
- Added glossary term 'Amended ATM Facility' with revised capitalization of 'our' to 'Our' (filed 2026-05-05)
- Added glossary term 'Bayer' with revised capitalization of 'means' to 'Means' (filed 2026-05-05)
- Added glossary term 'Bayer License Agreement' with revised capitalization of 'means' to 'Means' (filed 2026-05-05)
- Added glossary term 'CEDAR-HCM' with revised capitalization of 'our' to 'Our' (filed 2026-05-05)
- Added glossary term 'cGCP' with revised capitalization of 'current' to 'Current' (filed 2026-05-05)
- Added glossary term 'cGLP' with revised capitalization of 'current' to 'Current' (filed 2026-05-05)
- Added glossary term 'cGMP' with revised capitalization of 'current' to 'Current' (filed 2026-05-05)
- Added glossary term 'COMET-HF' with revised capitalization of 'our' to 'Our' (filed 2026-05-05)
- Added glossary term 'Common Stock' with revised capitalization of 'our' to 'Our' (filed 2026-05-05)
- Added glossary term 'Corxel OM License Agreement' with revised capitalization and wording (filed 2026-05-05)
- Added glossary term 'CV' with capitalization change from lowercase 'cardiovascular' to 'Cardiovascular' (filed 2026-05-05)
- Added glossary term 'ESPP' with capitalization change from lowercase 'employee stock purchase plan' (filed 2026-05-05)
- Added glossary term 'HCM' with capitalization change from lowercase 'hypertrophic cardiomyopathy' (filed 2026-05-05)
- Added glossary term 'HFpEF' with capitalization change from lowercase 'heart failure with preserved ejection fraction' (filed 2026-05-05)
- Added glossary term 'HFrEF' with capitalization change from lowercase 'heart failure with reduced ejection fraction' (filed 2026-05-05)
- Added glossary term 'LVEF' with capitalization change from lowercase 'left ventricular ejection fraction' (filed 2026-05-05)
- Added glossary term 'LVOT' with capitalization change from lowercase 'left ventricular outflow tract' (filed 2026-05-05)
- Added glossary term 'LVOT-G' with capitalization change from lowercase 'left ventricular outflow tract gradient' (filed 2026-05-05)
- Added glossary term 'nHCM' with capitalization change from lowercase 'non-obstructive HCM' (filed 2026-05-05)
- Added glossary term 'NOLs' with capitalization change from lowercase 'net operating loss carryforward' (filed 2026-05-05)
- Added glossary term 'oHCM' with capitalization change from lowercase 'obstructive HCM' (filed 2026-05-05)
- Removed:
- Removed glossary term '2020 RTW Transactions' and its definition (filed 2025-11-05)
- Removed glossary term '2021 RTW Transactions' and its definition (filed 2025-11-05)
- Removed glossary term 'ACA' and its definition (filed 2025-11-05)
- Removed glossary term 'ARR' and its definition (filed 2025-11-05)
- Removed glossary term 'Astellas Agreement' and its definition (filed 2025-11-05)
- Removed glossary term 'Corxel Agreements' and its definition (filed 2025-11-05)
- Removed glossary term 'CPET' and its definition (filed 2025-11-05)
- Removed glossary term 'EEA' and its definition (filed 2025-11-05)
- Removed glossary term 'FSTA' and its definition (filed 2025-11-05)
- Removed glossary term 'ICER' and its definition (filed 2025-11-05)
- Removed glossary term 'IRB' and its definition (filed 2025-11-05)
- Removed glossary term 'Mavacamten Royalty' and its definition (filed 2025-11-05)
- Removed glossary term 'Ownership Change' and its definition (filed 2025-11-05)
- Reworded:
- Table of Contents page numbers changed: Item 1A. Risk Factors from 45 to 41; Item 2 from 61 to 56; Item 3 from 61 to 56; Item 4 from 61 to 56; Item 5 from 61 to 56; Item 6 from 62 to 57; SIGNATURES from 64 to 59 (filed 2026-05-05)
- Corxel OM License Agreement definition: capitalization of 'means' changed to 'Means' and 'we' changed to 'we' (no substantive change noted in wording; text truncated in older filing)
- Notes:
- The older filing text appears truncated at the end of the glossary, cutting off mid-definition for 'REMS'; comparison limited to complete entries
- Older filing contains page number references that differ from newer filing, likely due to document reorganization
- Capitalization changes throughout glossary terms (lowercase to uppercase initial letters) are systematic but may reflect style guide updates rather than substantive content changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 18 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 2 sells ($2M) — 2 selling insiders
- Last 90 days0 buys · 18 sells ($12M) — 6 selling insiders
- Last 180 days0 buys · 33 sells ($21M) — 8 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-30. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about CYTK's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 4 matched disclosures for CYTK from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
4 institutional 13F filers reported holding CYTK as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 34,570,702
- Reported value $2,278,555,005
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 1 increased, 3 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
CYTK had 15,303,504 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
CYTK had 11.0% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.63 days to cover at the same settlement.
- Reported short interest (shares) 15,303,504
- Short interest (% of shares outstanding) 11.0%
- Prior settlement (shares) 17,051,981
- Reported change -10.25%
- Days to cover (reported) 9.63
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Bristol Myers Squibb (BMY)
- MyoKardia (acquired by BMY)
- Amgen (AMGN)
- Novartis (NVS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare CYTK vs…
CYTOKINETICS INC is found in…
Frequently asked questions
What does CYTOKINETICS INC (CYTK) do?
Cytokinetics is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of muscle activators and inhibitors for the treatment of severe cardiovascular and neuromuscular diseases. Its primary product pipeline includes clinical-stage therapies for conditions such as hypertrophic cardiomyopathy (HCM) and heart failure. The company collaborates with global partners for the development and commercialization of its therapeutics in international markets.
What sector is CYTOKINETICS INC (CYTK) in?
CYTOKINETICS INC (CYTK) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are CYTOKINETICS INC's (CYTK) competitors?
Notable peers of CYTOKINETICS INC (CYTK) include Bristol Myers Squibb, MyoKardia (acquired by BMY), Amgen and Novartis. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in CYTK?
Yes — we hold 4 matched STOCK Act disclosures for CYTK from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is CYTOKINETICS INC (CYTK) overbought or oversold right now?
CYTOKINETICS INC (CYTK) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 47, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on CYTK come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.